If your child has been diagnosed as small for their gestational age (SGA)—born smaller than expected for how long the pregnancy lasted—you may have heard about growth hormone therapy. A new analysis of 30 years of scientific research offers reassuring insights into how this treatment has matured and what it means for your family.
Researchers from Frontiers in Pediatrics examined nearly 800 scientific studies published between 1996 and 2025 on recombinant human growth hormone (rhGH) treatment for SGA children. The study tracked how the research landscape has shifted over three decades, revealing clear progress in how doctors approach this treatment.
The field has shifted from proving the treatment works to personalising it for each child
When growth hormone therapy was first approved for SGA children in 2001–2003, early studies focused on answering basic questions: Is this treatment safe? Does it make children taller? Over time, researchers moved toward understanding the biological mechanisms—the "why" behind growth challenges. Most recently, the field has shifted toward genetic testing and understanding individual differences, meaning doctors now have better tools to identify which children will benefit most from treatment.
Research activity has remained steady and strong, with studies being published at a consistent rate of 6.3% growth per year since 2011. This sustained progress suggests doctors and scientists continue to refine and improve how growth hormone therapy is used.
Today's doctors measure what actually matters to families
A significant shift has occurred in what researchers measure as "success." Doctors are no longer asking only "How much taller will my child grow?" but also "How will this affect my child's confidence, social development, and quality of life?" This patient-centred approach reflects what many Asian parents already prioritise: wellbeing beyond height alone.
The research now emphasises long-term outcomes for the child—emotional adjustment, school performance, and social confidence—alongside physical growth metrics. This holistic perspective represents real maturation in how the medical field thinks about treating growth challenges.
Singapore families can access increasingly evidence-based care
Singapore and Asia benefit from this global research progress. Leading research centres in the Netherlands, the United States, and Germany have collectively published thousands of studies, and paediatricians across Asia draw on these findings daily. The research shows that growth hormone therapy has become increasingly evidence-based and individualised rather than one-size-fits-all.
However, it's important to note this analysis examined the research field itself—how scientists have approached the topic over time—rather than conducting new clinical trials. Decisions about whether growth hormone therapy is right for your child should always be made with your paediatrician, who will consider your child's individual circumstances.